Anticoagulation Control in Different Ethnic Groups Receiving Vitamin K Antagonist for Stroke Prevention in Atrial Fibrillation

Vitamin K antagonist such as warfarin reduces the risk of stroke in atrial fibrillation (AF) patients. Since warfarin has a narrow therapeutic index, its administration needs to be regularly monitored to avoid any adverse clinical outcomes such as stroke and bleeding. The quality of anticoagulation...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Nur Azyyati Zawawi, Izzati Abdul Halim Zaki, Long Chiau Ming, Hui Poh Goh, Hanis Hanum Zulkifly
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	atrial fibrillation ethnicity time in therapeutic range (TTR) adverse clinical outcomes anticoagulant Diseases of the circulatory (Cardiovascular) system RC666-701
Acceso en línea:	https://doaj.org/article/60a277a526ab4bbf9921204e0a6b5032
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:60a277a526ab4bbf9921204e0a6b5032
record_format	dspace
spelling	oai:doaj.org-article:60a277a526ab4bbf9921204e0a6b50322021-11-16T05:21:03ZAnticoagulation Control in Different Ethnic Groups Receiving Vitamin K Antagonist for Stroke Prevention in Atrial Fibrillation2297-055X10.3389/fcvm.2021.736143https://doaj.org/article/60a277a526ab4bbf9921204e0a6b50322021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fcvm.2021.736143/fullhttps://doaj.org/toc/2297-055XVitamin K antagonist such as warfarin reduces the risk of stroke in atrial fibrillation (AF) patients. Since warfarin has a narrow therapeutic index, its administration needs to be regularly monitored to avoid any adverse clinical outcomes such as stroke and bleeding. The quality of anticoagulation control with warfarin therapy can be measured by using time in therapeutic range (TTR). This review focuses on the prevalence of AF, quality of anticoagulation control (TTR) and adverse clinical outcome in AF patients within different ethnic groups receiving warfarin therapy for stroke prevention. A literature search was conducted in Embase and PubMed using keywords of “prevalence,” “atrial fibrillation,” “stroke prevention,” “oral anticoagulants,” “warfarin,” “ethnicities,” “race” “time in therapeutic range,” “adverse clinical outcome,” “stroke, bleeding.” Articles published by 1st February 2020 were included. Forty-one studies were included in the final review consisting of AF prevalence (n = 14 studies), time in therapeutic range (n = 18 studies), adverse clinical outcome (n = 9 studies) within different ethnic groups. Findings indicate that higher prevalence of AF but better anticoagulation control among the Whites as compared to other ethnicities. Of note, non-whites had higher risk of strokes and bleeding outcomes while on warfarin therapy. Addressing disparities in prevention and healthcare resource allocation could potentially improve AF-related outcomes in minorities.Nur Azyyati ZawawiIzzati Abdul Halim ZakiIzzati Abdul Halim ZakiLong Chiau MingHui Poh GohHanis Hanum ZulkiflyHanis Hanum ZulkiflyFrontiers Media S.A.articleatrial fibrillationethnicitytime in therapeutic range (TTR)adverse clinical outcomesanticoagulantDiseases of the circulatory (Cardiovascular) systemRC666-701ENFrontiers in Cardiovascular Medicine, Vol 8 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	atrial fibrillation ethnicity time in therapeutic range (TTR) adverse clinical outcomes anticoagulant Diseases of the circulatory (Cardiovascular) system RC666-701
spellingShingle	atrial fibrillation ethnicity time in therapeutic range (TTR) adverse clinical outcomes anticoagulant Diseases of the circulatory (Cardiovascular) system RC666-701 Nur Azyyati Zawawi Izzati Abdul Halim Zaki Izzati Abdul Halim Zaki Long Chiau Ming Hui Poh Goh Hanis Hanum Zulkifly Hanis Hanum Zulkifly Anticoagulation Control in Different Ethnic Groups Receiving Vitamin K Antagonist for Stroke Prevention in Atrial Fibrillation
description	Vitamin K antagonist such as warfarin reduces the risk of stroke in atrial fibrillation (AF) patients. Since warfarin has a narrow therapeutic index, its administration needs to be regularly monitored to avoid any adverse clinical outcomes such as stroke and bleeding. The quality of anticoagulation control with warfarin therapy can be measured by using time in therapeutic range (TTR). This review focuses on the prevalence of AF, quality of anticoagulation control (TTR) and adverse clinical outcome in AF patients within different ethnic groups receiving warfarin therapy for stroke prevention. A literature search was conducted in Embase and PubMed using keywords of “prevalence,” “atrial fibrillation,” “stroke prevention,” “oral anticoagulants,” “warfarin,” “ethnicities,” “race” “time in therapeutic range,” “adverse clinical outcome,” “stroke, bleeding.” Articles published by 1st February 2020 were included. Forty-one studies were included in the final review consisting of AF prevalence (n = 14 studies), time in therapeutic range (n = 18 studies), adverse clinical outcome (n = 9 studies) within different ethnic groups. Findings indicate that higher prevalence of AF but better anticoagulation control among the Whites as compared to other ethnicities. Of note, non-whites had higher risk of strokes and bleeding outcomes while on warfarin therapy. Addressing disparities in prevention and healthcare resource allocation could potentially improve AF-related outcomes in minorities.
format	article
author	Nur Azyyati Zawawi Izzati Abdul Halim Zaki Izzati Abdul Halim Zaki Long Chiau Ming Hui Poh Goh Hanis Hanum Zulkifly Hanis Hanum Zulkifly
author_facet	Nur Azyyati Zawawi Izzati Abdul Halim Zaki Izzati Abdul Halim Zaki Long Chiau Ming Hui Poh Goh Hanis Hanum Zulkifly Hanis Hanum Zulkifly
author_sort	Nur Azyyati Zawawi
title	Anticoagulation Control in Different Ethnic Groups Receiving Vitamin K Antagonist for Stroke Prevention in Atrial Fibrillation
title_short	Anticoagulation Control in Different Ethnic Groups Receiving Vitamin K Antagonist for Stroke Prevention in Atrial Fibrillation
title_full	Anticoagulation Control in Different Ethnic Groups Receiving Vitamin K Antagonist for Stroke Prevention in Atrial Fibrillation
title_fullStr	Anticoagulation Control in Different Ethnic Groups Receiving Vitamin K Antagonist for Stroke Prevention in Atrial Fibrillation
title_full_unstemmed	Anticoagulation Control in Different Ethnic Groups Receiving Vitamin K Antagonist for Stroke Prevention in Atrial Fibrillation
title_sort	anticoagulation control in different ethnic groups receiving vitamin k antagonist for stroke prevention in atrial fibrillation
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/60a277a526ab4bbf9921204e0a6b5032
work_keys_str_mv	AT nurazyyatizawawi anticoagulationcontrolindifferentethnicgroupsreceivingvitaminkantagonistforstrokepreventioninatrialfibrillation AT izzatiabdulhalimzaki anticoagulationcontrolindifferentethnicgroupsreceivingvitaminkantagonistforstrokepreventioninatrialfibrillation AT izzatiabdulhalimzaki anticoagulationcontrolindifferentethnicgroupsreceivingvitaminkantagonistforstrokepreventioninatrialfibrillation AT longchiauming anticoagulationcontrolindifferentethnicgroupsreceivingvitaminkantagonistforstrokepreventioninatrialfibrillation AT huipohgoh anticoagulationcontrolindifferentethnicgroupsreceivingvitaminkantagonistforstrokepreventioninatrialfibrillation AT hanishanumzulkifly anticoagulationcontrolindifferentethnicgroupsreceivingvitaminkantagonistforstrokepreventioninatrialfibrillation AT hanishanumzulkifly anticoagulationcontrolindifferentethnicgroupsreceivingvitaminkantagonistforstrokepreventioninatrialfibrillation
_version_	1718426667838341120

Anticoagulation Control in Different Ethnic Groups Receiving Vitamin K Antagonist for Stroke Prevention in Atrial Fibrillation

Ejemplares similares